Trial Profile
Pharmacokinetics and safety of LY2334737 in combination with docetaxel in patients with advanced solid tumors.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 02 Nov 2015
Price :
$35
*
At a glance
- Drugs LY 2334737 (Primary) ; Docetaxel
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 02 Nov 2015 New trial record